Analyst Reco. Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-11 pm EDT			5-day change	1st Jan Change
109.64 ^USD	-4.28%		-1.89%	+18.70%

Jul. 11	Wall Street Retreats as Investors Monitor Tariffs Updates, Bank Earnings Loom	MT
Jul. 11	Equity Markets Close Lower as Trade Tensions Escalate	MT

Analyst Reco.

HSBC Adjusts Price Target on Gilead Sciences to $91 From $93, Maintains Hold Rating	Jul. 11	MT
RBC Lifts Price Target on Gilead Sciences to $96 From $95, Keeps Sector Perform Rating	Jul. 07	MT
Wolfe Research Adjusts Price Target on Gilead Sciences to $135 From $115	Jun. 20	MT
Analyst recommendations: Lululemon, Micron, Carnival Corp, UnitedHealth…	Jun. 19
RBC Capital Raises Price Target on Gilead Sciences to $95 From $92, Keeps Sector Perform Rating	Jun. 11	MT
DBS Bank Adjusts Price Target on Gilead Sciences to $140 From $125, Maintains Buy Rating	Jun. 02	MT
Mizuho Adjusts Price Target on Gilead Sciences to $117 From $100, Maintains Outperform Rating	May. 05	MT
Wolfe Research Adjusts Gilead Sciences Price Target to $115 From $110	May. 02	MT
Analyst recommendations: Meta Platforms, Progressive, Equifax, SBA Communications, Cadence Design Systems...	Apr. 29
HSBC Adjusts Gilead Sciences Price Target to $93 From $82, Maintains Hold Rating	Apr. 28	MT
Oppenheimer Adjusts Price Target on Gilead Sciences to $125 From $132, Maintains Outperform Rating	Apr. 25	MT
Goldman Sachs Adjusts Gilead Sciences Price Target to $100 From $97, Maintains Neutral Rating	Apr. 25	MT
Morgan Stanley Raises Price Target on Gilead Sciences to $135 From $130, Keeps Overweight Rating	Apr. 25	MT
RBC Lifts Price Target on Gilead Sciences to $92 From $89, Keeps Sector Perform Rating	Apr. 25	MT
TD Cowen Adjusts Gilead Sciences Price Target to $110 From $100, Maintains Buy Rating	Apr. 23	MT
BMO Capital Adjusts Gilead Sciences Price Target to $120 From $115	Apr. 17	MT
Leerink Partners Adjusts Price Target on Gilead Sciences to $105 From $104, Keeps Outperform Rating	Apr. 17	MT
Goldman Sachs Adjusts Price Target on Gilead Sciences to $97 From $96, Maintains Neutral Rating	Apr. 15	MT
RBC Trims Price Target on Gilead Sciences to $89 From $90, Keeps Sector Perform Rating	Apr. 03	MT
JPMorgan Adjusts Price Target on Gilead Sciences to $130 From $120, Maintains Overweight Rating	Mar. 27	MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $130 From $123, Keeps Overweight Rating	Mar. 11	MT
BofA Securities Adjusts Gilead Sciences Price Target to $126 From $116, Maintains Buy Rating	Mar. 05	MT
Wells Fargo Adjusts Price Target on Gilead Sciences to $140 From $120, Keeps Overweight Rating	Mar. 05	MT
Oppenheimer Adjusts Price Target on Gilead Sciences to $132 From $115, Keeps Outperform Rating	Mar. 04	MT
Jefferies & Co. Adjusts Gilead Sciences Price Target to $130 From $115, Maintains Buy Rating	Feb. 28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Time To Grow PFL Fanbase, Revenue: CEO John Martin

July 11, 2025 at 04:09 am EDT